Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Phoenix, Arizona, United States
Clinical Trial Site
Bakersfield, California, United States
Clinical Trial Site
Beverly Hills, California, United States
Clinical Trial Site
Fullerton, California, United States
Clinical Trial Site
Irvine, California, United States
Clinical Trial Site
La Jolla, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Modesto, California, United States
Start Date
September 11, 2024
Primary Completion Date
September 11, 2026
Completion Date
February 1, 2028
Last Updated
January 12, 2026
371
ACTUAL participants
Brepocitinib PO QD
DRUG
Placebo PO QD
DRUG
Lead Sponsor
Priovant Therapeutics, Inc.
NCT07218770
NCT05486468
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02706704